218 related articles for article (PubMed ID: 37236412)
21. Positive allosteric modulators of α7* or β2* nicotinic acetylcholine receptors trigger different kinase pathways in mitochondria.
Uspenska K; Lykhmus O; Arias HR; Pons S; Maskos U; Komisarenko S; Skok M
Int J Biochem Cell Biol; 2018 Jun; 99():226-235. PubMed ID: 29704624
[TBL] [Abstract][Full Text] [Related]
22. An Evolving Therapeutic Rationale for Targeting the α
Deutsch SI; Burket JA
Curr Top Behav Neurosci; 2020; 45():167-208. PubMed ID: 32468495
[TBL] [Abstract][Full Text] [Related]
23. Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor.
Li Q; Nemecz Á; Aymé G; Dejean de la Bâtie G; Prevost MS; Pons S; Barilone N; Baachaoui R; Maskos U; Lafaye P; Corringer PJ
Cell Mol Life Sci; 2023 May; 80(6):164. PubMed ID: 37231269
[TBL] [Abstract][Full Text] [Related]
24. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.
Williams DK; Wang J; Papke RL
Biochem Pharmacol; 2011 Oct; 82(8):915-30. PubMed ID: 21575610
[TBL] [Abstract][Full Text] [Related]
25. Selective alpha7 nicotinic acetylcholine receptor ligands.
Mazurov A; Hauser T; Miller CH
Curr Med Chem; 2006; 13(13):1567-84. PubMed ID: 16787204
[TBL] [Abstract][Full Text] [Related]
26. Potentiation and allosteric agonist activation of α7 nicotinic acetylcholine receptors: binding sites and hypotheses.
Sanders VR; Millar NS
Pharmacol Res; 2023 May; 191():106759. PubMed ID: 37023990
[TBL] [Abstract][Full Text] [Related]
27. α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.
Mucchietto V; Fasoli F; Pucci S; Moretti M; Benfante R; Maroli A; Di Lascio S; Bolchi C; Pallavicini M; Dowell C; McIntosh M; Clementi F; Gotti C
Br J Pharmacol; 2018 Jun; 175(11):1957-1972. PubMed ID: 28726253
[TBL] [Abstract][Full Text] [Related]
28. Calcium activity in response to nAChR ligands in murine bone marrow granulocytes with different Gr-1 expression.
Serov D; Tikhonova I; Safronova V; Astashev M
Cell Biol Int; 2021 Jul; 45(7):1533-1545. PubMed ID: 33739565
[TBL] [Abstract][Full Text] [Related]
29. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions.
Huang X; Zheng F; Chen X; Crooks PA; Dwoskin LP; Zhan CG
J Med Chem; 2006 Dec; 49(26):7661-74. PubMed ID: 17181149
[TBL] [Abstract][Full Text] [Related]
30. Silent agonists for α7 nicotinic acetylcholine receptors.
Papke RL; Quadri M; Gulsevin A
Pharmacol Res; 2023 Apr; 190():106736. PubMed ID: 36940890
[TBL] [Abstract][Full Text] [Related]
31. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?
Thomsen MS; Mikkelsen JD
Curr Drug Targets; 2012 May; 13(5):707-20. PubMed ID: 22300038
[TBL] [Abstract][Full Text] [Related]
32. Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro.
Rousseau SJ; Jones IW; Pullar IA; Wonnacott S
Neuropharmacology; 2005 Jul; 49(1):59-72. PubMed ID: 15992581
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.
Jackson A; Papke RL; Damaj MI
Psychopharmacology (Berl); 2018 Jul; 235(7):1897-1905. PubMed ID: 29549391
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Targeting of
Papke RL; Horenstein NA
Pharmacol Rev; 2021 Jul; 73(3):1118-1149. PubMed ID: 34301823
[TBL] [Abstract][Full Text] [Related]
35. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist.
Whiteaker P; Christensen S; Yoshikami D; Dowell C; Watkins M; Gulyas J; Rivier J; Olivera BM; McIntosh JM
Biochemistry; 2007 Jun; 46(22):6628-38. PubMed ID: 17497892
[TBL] [Abstract][Full Text] [Related]
36. A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE.
Godin JR; Roy P; Quadri M; Bagdas D; Toma W; Narendrula-Kotha R; Kishta OA; Damaj MI; Horenstein NA; Papke RL; Simard AR
Brain Behav Immun; 2020 Jul; 87():286-300. PubMed ID: 31874200
[TBL] [Abstract][Full Text] [Related]
37. New quinoline derivatives as nicotinic receptor modulators.
Manetti D; Bellucci C; Dei S; Teodori E; Varani K; Spirova E; Kudryavtsev D; Shelukhina I; Tsetlin V; Romanelli MN
Eur J Med Chem; 2016 Mar; 110():246-58. PubMed ID: 26840365
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.
Iwamoto K; Mata D; Linn DM; Linn CL
Neuroscience; 2013 May; 237():184-98. PubMed ID: 23402849
[TBL] [Abstract][Full Text] [Related]
39. Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors.
Matera C; Papotto C; Dallanoce C; De Amici M
Pharmacol Res; 2023 Aug; 194():106813. PubMed ID: 37302724
[TBL] [Abstract][Full Text] [Related]
40. The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α represents a new antinociceptive signaling pathway in mice.
Donvito G; Bagdas D; Toma W; Rahimpour E; Jackson A; Meade JA; AlSharari S; Kulkarni AR; Ivy Carroll F; Lichtman AH; Papke RL; Thakur GA; Imad Damaj M
Exp Neurol; 2017 Sep; 295():194-201. PubMed ID: 28606623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
